$MGNC
Mag Magna Corp

2023 Q4 Form 10-Q Financial Statement

#000194986423000029 Filed on December 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023 Q2
Revenue $1.400K
YoY Change
Cost Of Revenue $1.400K
YoY Change
Gross Profit $1.400K $0.00
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.071K $7.424K
YoY Change 84.28%
Operating Profit $5.671K -$7.424K
YoY Change -247.8%
Interest Expense $5.00 $5.00
YoY Change
% of Operating Profit 0.09%
Other Income/Expense, Net $5.00 $5.00
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$5.666K -$7.419K
YoY Change 47.78%
Net Earnings / Revenue -404.71%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 4.500M shares
Diluted Shares Outstanding 4.500M shares 4.500M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $4.484K $4.513K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $9.000K
Receivables
Other Receivables
Total Short-Term Assets $4.00 $4.513K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $15.64K $8.206K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $20.12K $17.21K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $4.00 $4.513K
Total Long-Term Assets $20.12K $17.21K
Total Assets $20.12K $21.72K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.63K $35.14K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $46.63K $35.14K
Total Long-Term Liabilities
Total Liabilities $46.63K $35.14K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$13.09K $17.92K
YoY Change
Common Stock $4.500K $4.500K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$26.50K -$20.84K -$13.42K
YoY Change
Total Liabilities & Shareholders Equity $20.12K $21.72K
YoY Change

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$5.666K -$7.419K
YoY Change 47.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.635K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.635K
YoY Change
NET CHANGE
Cash From Operating Activities -$6.635K
Cash From Investing Activities
Cash From Financing Activities $6.635K
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$6.635K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Central Index Key
EntityCentralIndexKey
0001949864
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
usd
CY2022Q4 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2023Q4 us-gaap Proceeds From Customers
ProceedsFromCustomers
usd
CY2022Q4 us-gaap Proceeds From Customers
ProceedsFromCustomers
usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
usd
us-gaap Proceeds From Customers
ProceedsFromCustomers
usd
CY2022Q4 us-gaap Gross Profit
GrossProfit
usd
us-gaap Gross Profit
GrossProfit
usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-10-31
dei Entity File Number
EntityFileNumber
333-268561
dei Entity Registrant Name
EntityRegistrantName
MAG MAGNA CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1626237
dei Entity Address Address Line1
EntityAddressAddressLine1
325 W Washington St Ste 2877
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92103
dei City Area Code
CityAreaCode
620
dei Local Phone Number
LocalPhoneNumber
4692043
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4732000 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4484 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4513 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
4513 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15639 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8206 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
15639 usd
CY2023Q2 us-gaap Other Assets
OtherAssets
17206 usd
CY2023Q4 us-gaap Assets
Assets
20123 usd
CY2023Q2 us-gaap Assets
Assets
21719 usd
CY2023Q4 us-gaap Loans And Leases Receivable Loans In Process
LoansAndLeasesReceivableLoansInProcess
46625 usd
CY2023Q2 us-gaap Loans And Leases Receivable Loans In Process
LoansAndLeasesReceivableLoansInProcess
35136 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46625 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
35136 usd
CY2023Q4 us-gaap Liabilities
Liabilities
46625 usd
CY2023Q2 us-gaap Liabilities
Liabilities
35136 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4500000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4500000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4500000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4500000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4500 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
4500 usd
CY2023Q4 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
-17917 usd
CY2023Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
1 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13085 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17918 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
26502 usd
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
13417 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20123 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21719 usd
CY2023Q4 us-gaap Revenues
Revenues
1400 usd
us-gaap Revenues
Revenues
1400 usd
CY2023Q4 us-gaap Gross Profit
GrossProfit
1400 usd
us-gaap Gross Profit
GrossProfit
1400 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7071 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3837 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14496 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6899 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
7071 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
3837 usd
us-gaap Operating Expenses
OperatingExpenses
14496 usd
us-gaap Operating Expenses
OperatingExpenses
6899 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
5671 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3837 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
13096 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6899 usd
CY2023Q4 us-gaap Interest Income Other
InterestIncomeOther
6 usd
CY2022Q4 us-gaap Interest Income Other
InterestIncomeOther
3 usd
us-gaap Interest Income Other
InterestIncomeOther
11 usd
us-gaap Interest Income Other
InterestIncomeOther
5 usd
CY2023Q4 us-gaap Interest Expense Other
InterestExpenseOther
6 usd
CY2022Q4 us-gaap Interest Expense Other
InterestExpenseOther
3 usd
us-gaap Interest Expense Other
InterestExpenseOther
11 usd
us-gaap Interest Expense Other
InterestExpenseOther
5 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
5666 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3834 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-13085 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6894 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4500000 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4500000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4500000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4500000 shares
CY2022Q2 us-gaap Shares Issued
SharesIssued
4500000 shares
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4501 usd
us-gaap Net Income Loss
NetIncomeLoss
-6894 usd
CY2023Q2 us-gaap Shares Outstanding
SharesOutstanding
4500000 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-13417 usd
us-gaap Net Income Loss
NetIncomeLoss
-13085 usd
CY2022Q3 us-gaap Shares Issued
SharesIssued
4500000 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1441 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3834 usd
CY2002Q4 us-gaap Shares Issued
SharesIssued
4500000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2393 usd
CY2023Q3 us-gaap Shares Outstanding
SharesOutstanding
4500000 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-20836 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-5666 usd
CY2023Q4 us-gaap Shares Outstanding
SharesOutstanding
4500000 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-26502 usd
us-gaap Net Income Loss
NetIncomeLoss
-13085 usd
us-gaap Net Income Loss
NetIncomeLoss
-6894 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1567 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
164 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
9000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
6450 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2950 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
20518 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16130 usd
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
9000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
11489 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
16135 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11489 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16135 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4513 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4501 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4484 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4506 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_zWGdZgNp5xIi" style="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0 9pt; text-indent: 0.5in"><i><span id="xdx_867_zmggLpi09el2">Use of Estimates</span></i></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q4 us-gaap Loans Payable
LoansPayable
78067 usd
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4500000

Files In Submission

Name View Source Status
0001949864-23-000029-index-headers.html Edgar Link pending
0001949864-23-000029-index.html Edgar Link pending
0001949864-23-000029.txt Edgar Link pending
0001949864-23-000029-xbrl.zip Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mag10q_31102023.htm Edgar Link pending
MetaLinks.json Edgar Link pending
none-20231031.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
none-20231031_lab.xml Edgar Link unprocessable
none-20231031_cal.xml Edgar Link unprocessable
none-20231031_def.xml Edgar Link unprocessable
none-20231031_pre.xml Edgar Link unprocessable
mag10q_31102023_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending